- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Naviscan readies PET biopsy
PET niche developer Naviscan arrived at the RSNA meeting with permission from the FDA to launch its Stereo Navigator, a biopsy guidance feature for its breast-specific PET scanner. Stereo Navigator can localize lesions as small as 2 mm. It uses a stereotactic frame fixed between the scanner’s paddles to guide a biopsy needle into the breast. Localization is verified using a PET-visible line source inserted into the needle track. This allows the user to confirm trajectory and position. The PET-guidance accessory is compatible with biopsy devices from Ethicon Endo-Surgery, Hologic, and SenoRx.
PET niche developer Naviscan arrived at the RSNA meeting with permission from the FDA to launch its Stereo Navigator, a biopsy guidance feature for its breast-specific PET scanner. Stereo Navigator can localize lesions as small as 2 mm. It uses a stereotactic frame fixed between the scanner's paddles to guide a biopsy needle into the breast. Localization is verified using a PET-visible line source inserted into the needle track. This allows the user to confirm trajectory and position. The PET-guidance accessory is compatible with biopsy devices from Ethicon Endo-Surgery, Hologic, and SenoRx.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.
